

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE SERIAL NUMBER 003300293 EXAMINER HOFVANDER 08/070,455 11/24/93 FOX.D PAPER NUMBER 18M2/0202-**ART UNIT** BENTON S. DUFFETT, JR. BURNS, DOANE, SWECKER & MATHIS GEORGE MASON BUILDING WASHINGTON & PRINCE STS., P.O. BOX 1404 1803 DATE MAILED: ALEXANDRIA, VA 22313-1404 02/02/95 This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS Responsive to communication filed on 10/3/94 1/7/94 This action is made final. _ days from the date of this letter. A shortened statutory period for response to this action is set to expire Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133 Part 1 THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION: 2. Notice of Draftsman's Patent Drawing Review, PTO-948. Notice of References Cited by Examiner, PTO-892. 4. Notice of Informal Patent Application, PTO-152. 3. Notice of Art Cited by Applicant, PTO-1449. 5. Information on How to Effect Drawing Changes, PTO-1474... Part II SUMMARY OF ACTION are pending in the application. are withdrawn from consideration. Of the above, claims ____ have been cancelled. 3. Claims 4. Claims are objected to. 5. Claims are subject to restriction or election requirement. 6. Claims This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes. 8. Formal drawings are required in response to this Office action. . Under 37 C.F.R. 1.84 these drawings 9. The corrected or substitute drawings have been received on _ are ☐ acceptable; ☐ not acceptable (see explanation or Notice of Draftsman's Patent Drawing Review, PTO-948). 10. The proposed additional or substitute sheet(s) of drawings, filed on _ _____. has (have) been approved by the examiner; disapproved by the examiner (see explanation). 11. The proposed drawing correction, filed _______ has been approved; disapproved (see explanation). 12. Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has Deen received not been received __ ; filed on __ ☐ been filed in parent application, serial no. __ 13. Since this application apppears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. 14. Other

607

Serial No. 08/070,455 Art Unit 1803

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1803.

The rejection of the claims under 35 U.S.C. 101 has been withdrawn in view of the amendment of 3 October 1994.

The rejections of the claims under 35 U.S.C. 112, second paragraph, have been withdrawn in view of the amendment of 3 October 1994, except as indicated below.

Claims 1, 4 and 6-21 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1, 4, 6-8, 10 and 21 (newly submitted), and claims 9 and 11-20 (dependent thereon), are indefinite in their recitation of "essentially", as stated in the last office action for claims 1, 4-8 and 10, and claims 9 and 11-20 (dependent thereon). Claim 9 remains indefinite for failing to employ proper Markush terminology, as stated in the last office action for claims 1, 4, 7 and 9-10.

Applicants' arguments filed 3 October 1994 have been fully considered but they are not deemed to be persuasive. Applicants urge that rejection of the claims as being indefinite is improper, given the occurrence of minor variations in gene sequence which would not affect gene function. The Examiner maintains that the modification of even a single nucleotide may

15

result in the change in reading frame and the resultant loss of activity, so that claims drawn to DNA "essentially" having a particular sequence are indefinite in that the metes and bounds and function of such a sequence is unclear. If Applicants wish to claim any gene which will encode a particular portion of the potato GBSS protein, language such as, --a nucleotide sequence [any of 6-20, as encoding the amino acid sequence of SEQ ID No. appropriately corresponds to the nucleotide sequences of SEQ ID If Applicants wish to claim any 1-3]--, is suggested. Nos. promoter from the potato GBSS gene, language such as isolated promoter from the potato gene coding for granule-bound starch synthase (GBSS)-- is suggested. However, Applicants are cautioned against submitting an amendment after final which makes extensive revisions to the claims or adds a substantial number of new claims with varying scope.

The rejections of the claims under 35 U.S.C. 102(a) have been withdrawn in view of the submission of the certified translation of the Swedish priority document and the demonstration that Rohde et al. was distributed after the filing date of the foreign priority document.

The rejections of the claims under 35 U.S.C. 102(b) have been withdrawn in view of the amendment of 3 October 1994, which cancelled claim 5 and changed claim 6 to recite an isolated gene.

The rejections of the claims under 35 U.S.C. 102 or 103 have been withdrawn in view of the arguments in the amendment of 3

October 1994 and the demonstration in the Persson declaration of 7 November 1994 that the presence of the claimed antisense construct resulted in the production of potato tubers with materially different types of starch.

The rejections of the claims under 35 U.S.C. 103 have been withdrawn in view of the arguments in the amendment of 3 October 1994 regarding the lack of reasonable expectation of success that the antisense GBSS gene from potato would successfully inhibit amylose accumulation in tubers, given the lack of consistency of the results of Visser and the demonstration by references submitted with the amendment of 3 October 1994 that the relationship between amylose accumulation and the GBSS gene family was unclear.

No claim is allowed.

Applicant's amendment necessitated the new grounds of rejection. Accordingly, THIS ACTION IS MADE FINAL. See M.P.E.P. 5 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL IS SET ACTION TO EXPIRE THREE MONTHS FROM THE DATE OF ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE TO 37 C.F.R. DATE OF THE A § 1.136(a) WILL BE CALCULATED ADVISORY ACTION. WILL THE IN NO EVENT STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

Serial No. 08/070,455 Art Unit 1803

-5-

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David T. Fox whose telephone number is (703) 308-0280.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

January 27, 1995

DAVID T. FOX
PRIMARY EXAMINER
GROUP 180

5